Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

由 Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E., Chow, Laura Q. M., Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice, Antonia, Scott, Wohlleber, Markus, Gerber, David E., Czyzewicz, Grzegorz, Spigel, David R., Crino, Lucio, Eberhardt, Wilfried Enst Erich, Li, Ang, Marimuthu, Sathiya, Brahmer, Julie
發表在 J Clin Oncol (2021)